RxDoctor Payments Data

Daniel Amsler

Optometrist · Brookville, PANPI 1891786596

Payments from drug & device makers

$556in general payments, 2019–2025

Across 23 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$188
  • Oyster Point Pharma, Inc.$116
  • AbbVie$88
  • Alcon$68
  • Rxsight Inc$25
  • Shire North American Group Inc$21
  • plus $49 from 4 others

What the payments were for

  • Food & beverage$556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$556 in reported general payments places this provider in the 40th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$96,310
Medicare patients
571
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost113$51,618
RestasisCyclosporine30$21,854
RocklatanNetarsudil Mesylat/Latanoprost34$13,520
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol72$13,405
Cyclosporine30$12,438
SimbrinzaBrinzolamide/Brimonidine Tart46$10,309
Latanoprost421$5,552
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat140$2,884
CombiganBrimonidine Tartrate/Timolol12$2,300
Prednisolone Acetate69$2,137
Brimonidine Tartrate30$1,717
Timolol Maleate73$1,361
Fluorometholone17$1,348
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha122$1,344
Dorzolamide-TimololDorzolamide/Timolol/Pf11$690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$88$75,772155 claims
AlconSimbrinza$68$10,30946 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Brookville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →